We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TRAK:NYSEReposiTrak, Inc. Analysis

Data as of 2026-08-02 - not real-time

$8.44

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

ReposiTrak is trading at $8.44, well above the DCF‑derived fair value of roughly $5.20, indicating a material overvaluation despite a P/E of 22.8 that sits below the software industry average of 32.8. The price sits below the 20‑day (8.73) and 50‑day (9.32) simple moving averages and is also under the 200‑day SMA (10.60), reinforcing a bearish technical backdrop. RSI at 42 suggests neutral momentum, while the MACD line has turned marginally bullish (histogram +0.02) but remains deep in negative territory, hinting at limited upside. Volume is on an increasing trend, yet the stock is confined between a support of $7.77 and resistance near $9.78, leaving little room for a breakout. On the fundamentals side, revenue has slipped 0.5% year‑over‑year, but gross margin remains robust at 85% and operating margin above 38%, reflecting a strong cost structure. Cash balances of $26.4 M dwarf the modest debt load of $0.35 M, yielding a very low leverage profile and supporting the current 0.95% dividend. The payout ratio of roughly 21% and consistent dividend history point to a sustainable income stream. Return on equity of 14.7% and ROA of 8.4% are respectable for a small‑cap tech firm, but the lack of top‑line growth tempers enthusiasm. The recent partnership with the National Grocers Association and the expansion of the Traceability Network provide a narrative catalyst, yet the market’s “Extreme Greed” sentiment (fear‑greed index 92.9) may be overstating near‑term upside. Overall, the blend of bearish technical signals, overvaluation relative to intrinsic estimates, and modest growth prospects suggest caution, while the solid balance sheet and dividend yield offer a modest defensive floor.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Price below key moving averages indicating bearish bias
  • Proximity to support level with limited upside to resistance
  • High 30‑day volatility and overvaluation versus DCF

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Sustainable dividend and strong cash position
  • Potential upside from partnership and traceability network expansion
  • Continued revenue contraction limiting earnings growth

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Value tilt with P/E below industry average and solid margins
  • Low leverage and ample liquidity supporting dividend continuity
  • Long‑term tailwinds in regulatory compliance and supply‑chain traceability

Key Metrics & Analysis

Financial Health

Revenue Growth-0.50%
Profit Margin31.05%
P/E Ratio22.8
ROE14.66%
ROA8.41%
Debt/Equity0.69
P/B Ratio3.0
Op. Cash Flow$7.5M
Free Cash Flow$5.3M
Industry P/E32.8

Technical Analysis

TrendBearish
RSI42.4
Support$7.77
Resistance$9.78
MA 20$8.73
MA 50$9.32
MA 200$10.60
MACDBullish
VolumeIncreasing
Fear & Greed Index92.88

Valuation

Fair Value$5.20
Target Price$16.00
Upside/Downside89.57%
GradeOvervalued
TypeValue
Dividend Yield0.95%

Risk Assessment

Beta0.76
Volatility44.48%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.